Arrayjet wins six-figure deal with institute in Australia

Life sciences firm Arrayjet, which specialises in printing services used for medical screening, has secured a contract worth about £300,000 with a flagship biomedical research facility.

The Roslin-based company has joined forces with Griffith Universitys pioneering Institute for Glycomics in Queensland. Picture: Youtube

The Roslin-based company has joined forces with Griffith University’s pioneering Institute for Glycomics in Queensland, which works to develop “the next generation of drugs and vaccines to fight diseases of global impact” and focuses on the structure and function of sugars in biological systems. The deal will see Arrayjet provide “the most advanced instrumentation printing technology available” to print glycan arrays, which help scientists understand how complex sugar molecules on cell surfaces relate to particular biological functions.

Arrayjet said its involvement is saving the Australian bio-analytical facility “an enormous amount of time” and making it a world-leader in its field.

Iain McWilliam, chief executive of Arrayjet, said it was “delighted” to have been chosen to partner with the institute “at this exciting phase of their development”.

The two organisations are also collaborating to provide life-science companies throughout the Asia-Pacific with a consulting service providing microarray analytics for a range of diagnostic applications.

McWilliam added: “What’s more, we are building a solid customer base across the Asia Pacific Rim, and for an SME with its headquarters in Midlothian, Scotland, we are delighted with our international reach and impact.”

Chris Davis, general manager at the Institute for Glycomics, said: “As an established world-leader in glycomics translational research, we are delighted to work with Arrayjet to further build translational capacity in our state-of-the-art glyco-bioanalytical facility.”

Among recent contract wins for Arrayjet are a £350,000 order from Chinese government-backed life sciences company CapitalBio that makes detection kits for conditions such as infant deafness and Down’s syndrome, and a £150,000 contract with Swiss-based Philip Morris Products, a subsidiary of tobacco giant Philip Morris International.